Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HZ-A-018 in B-Cell Lymphoma
NCT04173455Phase 1Unknown
- Sponsor
- First Affiliated Hospital, Zhejiang University School of Medicine
- Start
- Oct 2019
- Primary completion
- Sep 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of HZ-A-018 in B cell lymphoma, sponsored by First Affiliated Hospital, Zhejiang University School of Medicine. Primary endpoints: Dose Limiting Toxicity at 28 days, Maximum Tolerated Dose at 28 days and 1 more. Status: unknown.
02
Drugs
HZ-A-018
03
Conditions
B cell lymphoma
Beyond the preview
Go deeper on NCT04173455.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04173455.